Physician

Mark J Biagtan

According to 2025 Medicare claims, Mark Biagtan (NPI: 1376707307) practices allergy/immunology in the Madison, WI market, with the plurality of this provider's patient population coming from Dane, WI. This provider's primary affiliated billing organization is UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION, INC (NPI: 1598784555; TIN: 391824445) and primary practice location at 53715-1348. Biagtan is affiliated with the UW Health ACO, Inc (ACO ID: A5500), participating under the MSSP model.

Biagtan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 439 traditional Medicare patients, billed 17,742 HCPCS/CPT codes, and received $545,121 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,165 prescription claims across 490 beneficiaries totaling $776,075 in drug costs, led by Fluticasone Propionate Hfa (Fluticasone Propionate). DME data shows 102 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $67,435 to $545,121. Similarly, Part D prescription costs have moved sharply higher in recent years, from $107,435 to $776,075. In contrast, DME billing represents a smaller volume and rose steadily, from $809 to $1,284.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	193	3,148	$67,435
2016	253	4,783	$103,681
2017	349	8,137	$198,018
2018	377	13,993	$394,767
2019	361	13,235	$372,049
2020	335	9,884	$311,565
2021	374	10,140	$365,466
2022	424	16,364	$525,343
2023	424	17,030	$549,246
2024	439	17,742	$545,121

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	114	666	$107,435
2016	160	860	$145,921
2017	286	1,518	$252,864
2018	355	2,480	$440,691
2019	355	2,501	$457,236
2020	366	2,599	$556,688
2021	436	2,761	$752,267
2022	493	3,408	$961,660
2023	492	3,485	$976,371
2024	490	3,165	$776,075

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	57	$794
2018	N/R	74	$2,284
2019	N/R	54	$1,720
2020	N/R	82	$1,862
2021	N/R	93	$1,759
2022	17	142	$2,725
2023	12	143	$2,354
2024	12	102	$2,477

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	102	115	$87
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	265	295	$59
94010	Test to measure expiratory airflow and volume	193	221	$17
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	138	148	$12
96372	Injection of drug or substance under skin or into muscle	39	314	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Fluticasone Propionate Hfa	Fluticasone Propionate	284	12,773	$126,293
Advair Hfa	Fluticasone Propion/Salmeterol	272	9,720	$111,843
Fasenra Pen	Benralizumab	16	896	$87,071
Xolair	Omalizumab	30	798	$70,801
Breo Ellipta	Fluticasone/Vilanterol	91	4,050	$50,255

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7626	Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg	N	N/R	23	$1,225
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	12	36	$905
J7620	Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme	N	N/R	21	$264
E0570	Nebulizer, with compressor	Y	N/R	22	$81

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Mark J. Biagtan?

Tedicare shows public-source Medicare data for Mark J. Biagtan (NPI 1376707307), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark J. Biagtan have ACO affiliation data?

Mark J. Biagtan is shown with ACO affiliation data for UW Health ACO, Inc (MSSP, ACO ID A5500).

What billing organization is linked to Mark J. Biagtan?

Mark J. Biagtan is linked to UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION, INC (billing NPI 1598784555) in the available physician profile data.

Does Mark J. Biagtan have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.